Feedback / Questions
ABO21009 - AbolerIS Pharma
https://www.prnewswire.com/news-releases/aboleris-pharma-announces-first-cohort-dosed-in-phase-1-study-of-abo21009-a-novel-anti-cd45rc-antibody-for-rheumatoid-arthritis-302447848.html
 
May 7, 2025
 
SHARE THIS
  • Print
  • Email
  • More sharing
    Reddit
    StumbleUpon
    Delicious